Philips stock weighs legal relief against fresh Respironics costs

Philips combined stronger operating momentum with continuing Respironics exposure in its third-quarter release on Tuesday, November 3, 2026. The health technology group said comparable order intake rose 8 percent and sales grew 3 percent, while it reiterated its full-year outlook. The company also reported that the Amsterdam Enterprise Chamber of the Court of Appeal had rejected requests from investors for an investigation linked to the Respironics recall.

Philips stock traded at 26.92 euros on Lang & Schwarz at 11:36 CET on Wednesday, November 11, 2026.

Growth broadens across key segments

Philips reported third-quarter sales of 4.4 billion euros and income from operations of 165 million euros. Adjusted EBITA margin expanded 70 basis points to 13.0 percent, with improvement across all business segments. Operating cash flow reached 544 million euros and free cash flow was 384 million euros.

Connected Care posted 5 percent comparable sales growth and a 13.3 percent adjusted EBITA margin, while Personal Health grew 8 percent with a 17.7 percent margin. Diagnosis & Treatment recorded flat comparable sales, as growth in Image Guided Therapy was offset by weaker Precision Diagnosis sales, including lower sales in China and the timing of ultrasound deliveries.

CEO Roy Jakobs said Philips was seeing broad-based order momentum and continued margin expansion. He pointed to demand for AI-enabled imaging, ultrasound and cloud solutions, while the company prepares to showcase further innovations at the RSNA conference later in November.

Respironics remains a material overhang

The legal update provides relief on one shareholder-led route, but it does not remove the wider consequences of the 2021 recall. Philips said Respironics reached an agreement in principle with the US Department of Justice covering previously disclosed criminal and civil investigations. The company recorded a 288 million euro provision in the third quarter and expects payment in the first quarter of 2027, subject to final documentation.

Philips said its outlook assumes the DOJ settlement payment and excludes other ongoing Respironics-related proceedings, including an investigation by US state attorneys general. That qualification keeps legal costs and execution around the recall relevant to the investment case even as operating margins improve.

The 2026 outlook calls for comparable sales growth of 3 to 4.5 percent, an adjusted EBITA margin of 13.5 to 14.0 percent and free cash flow of 1.5 to 1.7 billion euros. The margin target includes an estimated benefit of about 1 percentage point from a US tariff refund, while the cash-flow target includes a net benefit of about 200 million euros.

The Dutch market backdrop is covered in the AEX market reports.

Further developments, results and analysis are available in More news and analyses on Philips stock.